STX3
protein-codingsyntaxin 3, the group of Syntaxins
Gene summary
The gene is a member of the syntaxin family. The encoded protein is targeted to the apical membrane of epithelial cells where it forms clusters and is important in establishing and maintaining polarity necessary for protein trafficking involving vesicle fusion and exocytosis. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2010]
- STX3A
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~92.4 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0009635
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0030335
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0859170
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0859170
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0019118
Submitter: LiferaOmics
Genetic evidence – Published PMID: 38098057 – Reports multiple consanguineous families with non syndromic retinal degeneration, caused by a homozygous STX3 loss of function founder variant (NM_004177.5:c.786+190dup; truncating in ENST00000437946.2:c.455dup;p.(Asp152Glufs*11)). Family 1 (18DG0095 & 18DG0094) – Two affected siblings. Case level (biallelic predicted null in AR model; homozygous scored once; consanguinity −0.5 applied) = 1.0; segregation (affected sibling sharing genotype; not counted as independent probands) = 0.5; case control = 0; Family 1 total = 1.5. Family 2 – One unrelated proband with identical non syndromic retinal phenotype and the same homozygous LoF variant. Case level (biallelic predicted null in AR model; homozygous scored once; consanguinity −0.5 applied) = 1.0; segregation = 0; case control = 0; Family 2 total = 1.0. Family 3 – One unrelated proband with identical phenotype and the same homozygous LoF founder variant. Case level (biallelic predicted null in AR model; homozygous scored once; consanguinity −0.5 applied) = 1.0; segregation = 0; case control = 0; Family 3 total = 1.0. Published genetic evidence total = 3.5 / 12 Genetic evidence – Our cases Our cohort – Additional 19 consanguineous probands with isolated retinal dystrophy carrying the same homozygous STX3 LoF founder variant. Each family (one proband per family): Case level (biallelic predicted null in AR model; homozygous scored once; consanguinity −0.5 applied) = 1.0; segregation = 0; case control = 0. Our cases total = 19.0 / 12 → capped at 8.5 / 12 (12.0 overall cap retained when combined with published evidence, see below) Total genetic evidence (published + our cases) Published (3.5) + Our cases (19.0) = 22.5 → capped at 12.0 / 12 Experimental evidence – Published PMID:33974130 • Gene function / biological plausibility (retinal expression and localization) = 0.5 • Animal model (retina specific knockout causing retinal degeneration) = 2.0 Experimental evidence total = 2.5 / 6 Overall score • Genetic evidence = 12.0 • Experimental evidence = 2.5 • Overall score = 14.5
Inheritance Pattern: AR
Disease ID:MONDO:0009635
Submitter: Orphanet
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to STX3 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_004177.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 65 | 66 | |||
| missense | 86 | 4 | 2 | 92 | ||
| nonsense | 3 | 2 | 5 | |||
| start loss | 0 | |||||
| frameshift | 5 | 1 | 6 | |||
| splice donor/acceptor (+/-2bp) | 1 | 3 | 3 | 7 | ||
| Total | 9 | 6 | 90 | 69 | 2 | 176 |
Highest pathogenic variant AF is 0.00006404171
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_004168.1 | 10 | MANE Select | |
| Ensembl | ENSP00000338562.4 | 10 | MANE Select | |
| RefSeq | NP_001171511.1 | 10 | Standard | |
| RefSeq | NP_001427451.1 | 10 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Synaptic vesicle cycle - Homo sapiens (human)
- SNARE interactions in vesicular transport - Homo sapiens (human)
- Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics
- Synaptic Vesicle Pathway
- Other interleukin signaling
Biological Process
- intracellular protein transport
- exocytosis
- vesicle fusion
- positive regulation of cell population proliferation
- synaptic vesicle docking
Molecular Function
- SNARE binding
- SNAP receptor activity
- protein binding
- arachidonic acid binding
Cellular Component
- vacuole
- plasma membrane
- cell-cell junction
- synaptic vesicle
- endomembrane system
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000337979
- Coding exons
- 10
- Length
- 92426
- Individuals with no LoFs
- 125733
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 15
- Defined
- 125748
- p
- 0.0000596
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.0100 | 172 | 172 | 1.00 | 0.00000994 | 1922 |
| Missense (PolyPhen) | 64 | 73.143 | 0.87499 | 769 | ||
| Synonymous | -0.0709 | 66 | 65.3 | 1.01 | 0.00000411 | 521 |
| Loss of Function | 2.85 | 6 | 19.6 | 0.306 | 0.00000120 | 211 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0.000087 | 0.000087 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00011 | 0.00011 | rare |
| Finnish | 0.000046 | 0.000046 | rare |
| European (Non-Finnish) | 0.000073 | 0.000070 | rare |
| South Asian | 0.000033 | 0.000033 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Potentially involved in docking of synaptic vesicles at presynaptic active zones.;
Recessive Scores
- pRec
- 0.175
Intolerance Scores
- LoFtool
- 0.429
- RVIS EVS
- 0.4
- RVIS percentile EVS
- 76.15
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.917
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |